Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.
作者信息
Al-Bawardy Badr, Quraishi Mohammed Nabil
机构信息
Division of Gastroenterology and Hepatology, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11121, Saudi Arabia.
Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
出版信息
Therap Adv Gastroenterol. 2025 Mar 24;18:17562848251328606. doi: 10.1177/17562848251328606. eCollection 2025.
Abstract
摘要
相似文献
1
Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.作者对《口服万古霉素治疗原发性硬化性胆管炎相关炎症性肠病的有效性和安全性：系统评价与汇总分析》的评论
Therap Adv Gastroenterol. 2025 Mar 24;18:17562848251328606. doi: 10.1177/17562848251328606. eCollection 2025.
2
Comment on "Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis".关于“口服万古霉素治疗原发性硬化性胆管炎相关炎症性肠病的有效性和安全性：系统评价与汇总分析”的评论
Therap Adv Gastroenterol. 2025 Apr 21;18:17562848251332453. doi: 10.1177/17562848251332453. eCollection 2025.
3
The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review.口服万古霉素对原发性硬化性胆管炎患者炎症性肠病的疗效：一项系统评价
Inflamm Bowel Dis. 2025 Jul 7;31(7):2027-2035. doi: 10.1093/ibd/izae257.
4
Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.口服万古霉素治疗原发性硬化性胆管炎相关炎症性肠病的有效性和安全性：一项系统评价和汇总分析。
Therap Adv Gastroenterol. 2025 Jan 9;18:17562848241312766. doi: 10.1177/17562848241312766. eCollection 2025.
5
How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?原发性硬化性胆管炎和溃疡性结肠炎患者口服万古霉素治疗后，肠球菌属耐药性的出现频率如何？
Indian J Gastroenterol. 2022 Oct;41(5):519-524. doi: 10.1007/s12664-022-01286-9. Epub 2022 Oct 10.
6
Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.口服万古霉素对儿童原发性硬化性胆管炎的长期治疗：一种免疫调节抗生素。
J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):61-7. doi: 10.1097/MPG.0b013e31816fee95.
7
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures.原发性硬化性胆管炎-炎症性肠病中开放标签万古霉素治疗：结肠疾病活动改善及与宿主-微生物组-代谢组学特征变化的关联
J Crohns Colitis. 2025 Feb 4;19(2). doi: 10.1093/ecco-jcc/jjae189.
8
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.口服万古霉素与原发性硬化性胆管炎相关炎症性肠病（PSC-IBD）中改善炎症性肠病临床结局相关：来自儿科 PSC 联盟的匹配分析。
Aliment Pharmacol Ther. 2024 May;59(10):1236-1247. doi: 10.1111/apt.17936. Epub 2024 Mar 10.
9
Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.原发性硬化性胆管炎的药物干预：一项网状Meta分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011343. doi: 10.1002/14651858.CD011343.pub2.
10
Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis.用于无艰难梭菌感染的难治性炎症性肠病的长期口服万古霉素：来自原发性硬化性胆管炎的经验教训。
Med Hypotheses. 2020 Nov;144:110211. doi: 10.1016/j.mehy.2020.110211. Epub 2020 Aug 26.
本文引用的文献
1
Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.口服万古霉素治疗原发性硬化性胆管炎相关炎症性肠病的有效性和安全性：一项系统评价和汇总分析。
Therap Adv Gastroenterol. 2025 Jan 9;18:17562848241312766. doi: 10.1177/17562848241312766. eCollection 2025.
2
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures.原发性硬化性胆管炎-炎症性肠病中开放标签万古霉素治疗：结肠疾病活动改善及与宿主-微生物组-代谢组学特征变化的关联
J Crohns Colitis. 2025 Feb 4;19(2). doi: 10.1093/ecco-jcc/jjae189.
3
Oral vancomycin use and incidence of vancomycin-resistant enterococci: time-series analysis.口服万古霉素的使用与耐万古霉素肠球菌的发生率：时间序列分析
Antimicrob Resist Infect Control. 2024 Dec 2;13(1):143. doi: 10.1186/s13756-024-01498-y.
4
How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?原发性硬化性胆管炎和溃疡性结肠炎患者口服万古霉素治疗后，肠球菌属耐药性的出现频率如何？
Indian J Gastroenterol. 2022 Oct;41(5):519-524. doi: 10.1007/s12664-022-01286-9. Epub 2022 Oct 10.
5
The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation.口服万古霉素在诱导生物治疗经验性溃疡性结肠炎合并原发性硬化性胆管炎和肝移植患者缓解中的作用。
Clin J Gastroenterol. 2021 Feb;14(1):159-164. doi: 10.1007/s12328-020-01272-8. Epub 2020 Nov 1.
6
Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.口服万古霉素可诱导原发性硬化性胆管炎-溃疡性结肠炎患儿的结肠炎实现临床和黏膜缓解。
Gut. 2019 Aug;68(8):1533-1535. doi: 10.1136/gutjnl-2018-316599. Epub 2018 Aug 21.
7
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.与万古霉素相比， fidaxomicin 治疗艰难梭菌感染可减少耐万古霉素肠球菌和念珠菌属的定植和过度生长。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S121-6. doi: 10.1093/cid/cis440.
8
Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control.固有耐万古霉素革兰氏阳性菌：临床相关性及对感染控制的影响
J Hosp Infect. 1999 Aug;42(4):275-82. doi: 10.1053/jhin.1998.0605.
Zotero 插件